AMP German Cannabis Group Inc. and Aphria Inc.’s wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement covering joint marketing of sales for Aphria brand medical cannabis products for the German market. The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany. In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists. Hendrik Knopp, Managing Director of Aphria Germany GmbH mentioned, “We are proud to launch our high-quality medical cannabis under the Aphria brand in Germany with the support of AMP. This agreement provides the opportunity to expand the Aphria brand in Germany, one of our key international markets.”

Sean Hocking, Cannabis Law Report, 01/27/2021 20:48:00

Open article: